Eli Lilly completes $2.4bn acquisition of DICE Therapeutics

Pallavi Madhiraju- August 10, 2023 0

Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More

Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth

Pallavi Madhiraju- August 9, 2023 0

Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, ... Read More

Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal

Pallavi Madhiraju- June 20, 2023 0

Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More